By Tony Fong

NEW YORK (GenomeWeb News) – With this week's announcement of its acquisition of nucleic acid isolation technology firm Chemagen Biopolymer-Technologie, PerkinElmer is taking another step toward building out is molecular diagnostics portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.